Global Non-oncology Biopharmaceuticals Market Growth (Status and Outlook) 2025-2031

December 2025 | 141 pages | ID: G092330853DEN
LP Information

Abstracts

According to this study, the global Non-oncology Biopharmaceuticals market size will reach US$ 610830 million by 2031.

Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. This report studies Non-oncology biopharmaceutical which are the drugs that are used in the treatment of various diseases rather than cancer.

United States market for Non-oncology Biopharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Non-oncology Biopharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Non-oncology Biopharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Non-oncology Biopharmaceuticals players cover Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Non-oncology Biopharmaceuticals Industry Forecast” looks at past sales and reviews total world Non-oncology Biopharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-oncology Biopharmaceuticals sales for 2025 through 2031. With Non-oncology Biopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-oncology Biopharmaceuticals industry.

This Insight Report provides a comprehensive analysis of the global Non-oncology Biopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-oncology Biopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-oncology Biopharmaceuticals market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-oncology Biopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-oncology Biopharmaceuticals.

This report presents a comprehensive overview, market shares, and growth opportunities of Non-oncology Biopharmaceuticals market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Biologics
• Biosimilars

Segmentation by Application:

• Immunology
• Endocrinology
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Roche
• Sanofi
• Johnson & Johnson
• Pfizer
• Novo Nordisk
• Novartis
• Merck
• Teva
• Eli Lilly
• Bristol-Myers Squibb
• GlaxoSmithKline
• UCB Pharma
• Amgen
• AbbVie
• Takeda
• AstraZeneca
• Mylan
• LEO Pharma
• Boehringer Ingelheim
• Alexion Pharmaceuticals
• Elusys Therapeutics
• Swedish Orphan Biovitrum
• Biogen

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Non-oncology Biopharmaceuticals Market Size (2020-2031)
  2.1.2 Non-oncology Biopharmaceuticals Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Non-oncology Biopharmaceuticals by Country/Region (2020, 2024 & 2031)
2.2 Non-oncology Biopharmaceuticals Segment by Type
  2.2.1 Biologics
  2.2.2 Biosimilars
2.3 Non-oncology Biopharmaceuticals Market Size by Type
  2.3.1 Non-oncology Biopharmaceuticals Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Non-oncology Biopharmaceuticals Market Size Market Share by Type (2020-2025)
2.4 Non-oncology Biopharmaceuticals Segment by Application
  2.4.1 Immunology
  2.4.2 Endocrinology
  2.4.3 Others
2.5 Non-oncology Biopharmaceuticals Market Size by Application
  2.5.1 Non-oncology Biopharmaceuticals Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Non-oncology Biopharmaceuticals Market Size Market Share by Application (2020-2025)

3 NON-ONCOLOGY BIOPHARMACEUTICALS MARKET SIZE BY PLAYER

3.1 Non-oncology Biopharmaceuticals Market Size Market Share by Player
  3.1.1 Global Non-oncology Biopharmaceuticals Revenue by Player (2020-2025)
  3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Player (2020-2025)
3.2 Global Non-oncology Biopharmaceuticals Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 NON-ONCOLOGY BIOPHARMACEUTICALS BY REGION

4.1 Non-oncology Biopharmaceuticals Market Size by Region (2020-2025)
4.2 Global Non-oncology Biopharmaceuticals Annual Revenue by Country/Region (2020-2025)
4.3 Americas Non-oncology Biopharmaceuticals Market Size Growth (2020-2025)
4.4 APAC Non-oncology Biopharmaceuticals Market Size Growth (2020-2025)
4.5 Europe Non-oncology Biopharmaceuticals Market Size Growth (2020-2025)
4.6 Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Non-oncology Biopharmaceuticals Market Size by Country (2020-2025)
5.2 Americas Non-oncology Biopharmaceuticals Market Size by Type (2020-2025)
5.3 Americas Non-oncology Biopharmaceuticals Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Non-oncology Biopharmaceuticals Market Size by Region (2020-2025)
6.2 APAC Non-oncology Biopharmaceuticals Market Size by Type (2020-2025)
6.3 APAC Non-oncology Biopharmaceuticals Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Non-oncology Biopharmaceuticals Market Size by Country (2020-2025)
7.2 Europe Non-oncology Biopharmaceuticals Market Size by Type (2020-2025)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Non-oncology Biopharmaceuticals by Region (2020-2025)
8.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2020-2025)
8.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL NON-ONCOLOGY BIOPHARMACEUTICALS MARKET FORECAST

10.1 Global Non-oncology Biopharmaceuticals Forecast by Region (2026-2031)
  10.1.1 Global Non-oncology Biopharmaceuticals Forecast by Region (2026-2031)
  10.1.2 Americas Non-oncology Biopharmaceuticals Forecast
  10.1.3 APAC Non-oncology Biopharmaceuticals Forecast
  10.1.4 Europe Non-oncology Biopharmaceuticals Forecast
  10.1.5 Middle East & Africa Non-oncology Biopharmaceuticals Forecast
10.2 Americas Non-oncology Biopharmaceuticals Forecast by Country (2026-2031)
  10.2.1 United States Market Non-oncology Biopharmaceuticals Forecast
  10.2.2 Canada Market Non-oncology Biopharmaceuticals Forecast
  10.2.3 Mexico Market Non-oncology Biopharmaceuticals Forecast
  10.2.4 Brazil Market Non-oncology Biopharmaceuticals Forecast
10.3 APAC Non-oncology Biopharmaceuticals Forecast by Region (2026-2031)
  10.3.1 China Non-oncology Biopharmaceuticals Market Forecast
  10.3.2 Japan Market Non-oncology Biopharmaceuticals Forecast
  10.3.3 Korea Market Non-oncology Biopharmaceuticals Forecast
  10.3.4 Southeast Asia Market Non-oncology Biopharmaceuticals Forecast
  10.3.5 India Market Non-oncology Biopharmaceuticals Forecast
  10.3.6 Australia Market Non-oncology Biopharmaceuticals Forecast
10.4 Europe Non-oncology Biopharmaceuticals Forecast by Country (2026-2031)
  10.4.1 Germany Market Non-oncology Biopharmaceuticals Forecast
  10.4.2 France Market Non-oncology Biopharmaceuticals Forecast
  10.4.3 UK Market Non-oncology Biopharmaceuticals Forecast
  10.4.4 Italy Market Non-oncology Biopharmaceuticals Forecast
  10.4.5 Russia Market Non-oncology Biopharmaceuticals Forecast
10.5 Middle East & Africa Non-oncology Biopharmaceuticals Forecast by Region (2026-2031)
  10.5.1 Egypt Market Non-oncology Biopharmaceuticals Forecast
  10.5.2 South Africa Market Non-oncology Biopharmaceuticals Forecast
  10.5.3 Israel Market Non-oncology Biopharmaceuticals Forecast
  10.5.4 Turkey Market Non-oncology Biopharmaceuticals Forecast
10.6 Global Non-oncology Biopharmaceuticals Forecast by Type (2026-2031)
10.7 Global Non-oncology Biopharmaceuticals Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Non-oncology Biopharmaceuticals Forecast

11 KEY PLAYERS ANALYSIS

11.1 Roche
  11.1.1 Roche Company Information
  11.1.2 Roche Non-oncology Biopharmaceuticals Product Offered
  11.1.3 Roche Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Roche Main Business Overview
  11.1.5 Roche Latest Developments
11.2 Sanofi
  11.2.1 Sanofi Company Information
  11.2.2 Sanofi Non-oncology Biopharmaceuticals Product Offered
  11.2.3 Sanofi Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Sanofi Main Business Overview
  11.2.5 Sanofi Latest Developments
11.3 Johnson & Johnson
  11.3.1 Johnson & Johnson Company Information
  11.3.2 Johnson & Johnson Non-oncology Biopharmaceuticals Product Offered
  11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Johnson & Johnson Main Business Overview
  11.3.5 Johnson & Johnson Latest Developments
11.4 Pfizer
  11.4.1 Pfizer Company Information
  11.4.2 Pfizer Non-oncology Biopharmaceuticals Product Offered
  11.4.3 Pfizer Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Pfizer Main Business Overview
  11.4.5 Pfizer Latest Developments
11.5 Novo Nordisk
  11.5.1 Novo Nordisk Company Information
  11.5.2 Novo Nordisk Non-oncology Biopharmaceuticals Product Offered
  11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Novo Nordisk Main Business Overview
  11.5.5 Novo Nordisk Latest Developments
11.6 Novartis
  11.6.1 Novartis Company Information
  11.6.2 Novartis Non-oncology Biopharmaceuticals Product Offered
  11.6.3 Novartis Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Novartis Main Business Overview
  11.6.5 Novartis Latest Developments
11.7 Merck
  11.7.1 Merck Company Information
  11.7.2 Merck Non-oncology Biopharmaceuticals Product Offered
  11.7.3 Merck Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Merck Main Business Overview
  11.7.5 Merck Latest Developments
11.8 Teva
  11.8.1 Teva Company Information
  11.8.2 Teva Non-oncology Biopharmaceuticals Product Offered
  11.8.3 Teva Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Teva Main Business Overview
  11.8.5 Teva Latest Developments
11.9 Eli Lilly
  11.9.1 Eli Lilly Company Information
  11.9.2 Eli Lilly Non-oncology Biopharmaceuticals Product Offered
  11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 Eli Lilly Main Business Overview
  11.9.5 Eli Lilly Latest Developments
11.10 Bristol-Myers Squibb
  11.10.1 Bristol-Myers Squibb Company Information
  11.10.2 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Offered
  11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.10.4 Bristol-Myers Squibb Main Business Overview
  11.10.5 Bristol-Myers Squibb Latest Developments
11.11 GlaxoSmithKline
  11.11.1 GlaxoSmithKline Company Information
  11.11.2 GlaxoSmithKline Non-oncology Biopharmaceuticals Product Offered
  11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.11.4 GlaxoSmithKline Main Business Overview
  11.11.5 GlaxoSmithKline Latest Developments
11.12 UCB Pharma
  11.12.1 UCB Pharma Company Information
  11.12.2 UCB Pharma Non-oncology Biopharmaceuticals Product Offered
  11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.12.4 UCB Pharma Main Business Overview
  11.12.5 UCB Pharma Latest Developments
11.13 Amgen
  11.13.1 Amgen Company Information
  11.13.2 Amgen Non-oncology Biopharmaceuticals Product Offered
  11.13.3 Amgen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.13.4 Amgen Main Business Overview
  11.13.5 Amgen Latest Developments
11.14 AbbVie
  11.14.1 AbbVie Company Information
  11.14.2 AbbVie Non-oncology Biopharmaceuticals Product Offered
  11.14.3 AbbVie Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.14.4 AbbVie Main Business Overview
  11.14.5 AbbVie Latest Developments
11.15 Takeda
  11.15.1 Takeda Company Information
  11.15.2 Takeda Non-oncology Biopharmaceuticals Product Offered
  11.15.3 Takeda Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.15.4 Takeda Main Business Overview
  11.15.5 Takeda Latest Developments
11.16 AstraZeneca
  11.16.1 AstraZeneca Company Information
  11.16.2 AstraZeneca Non-oncology Biopharmaceuticals Product Offered
  11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.16.4 AstraZeneca Main Business Overview
  11.16.5 AstraZeneca Latest Developments
11.17 Mylan
  11.17.1 Mylan Company Information
  11.17.2 Mylan Non-oncology Biopharmaceuticals Product Offered
  11.17.3 Mylan Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.17.4 Mylan Main Business Overview
  11.17.5 Mylan Latest Developments
11.18 LEO Pharma
  11.18.1 LEO Pharma Company Information
  11.18.2 LEO Pharma Non-oncology Biopharmaceuticals Product Offered
  11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.18.4 LEO Pharma Main Business Overview
  11.18.5 LEO Pharma Latest Developments
11.19 Boehringer Ingelheim
  11.19.1 Boehringer Ingelheim Company Information
  11.19.2 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Offered
  11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.19.4 Boehringer Ingelheim Main Business Overview
  11.19.5 Boehringer Ingelheim Latest Developments
11.20 Alexion Pharmaceuticals
  11.20.1 Alexion Pharmaceuticals Company Information
  11.20.2 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Offered
  11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.20.4 Alexion Pharmaceuticals Main Business Overview
  11.20.5 Alexion Pharmaceuticals Latest Developments
11.21 Elusys Therapeutics
  11.21.1 Elusys Therapeutics Company Information
  11.21.2 Elusys Therapeutics Non-oncology Biopharmaceuticals Product Offered
  11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.21.4 Elusys Therapeutics Main Business Overview
  11.21.5 Elusys Therapeutics Latest Developments
11.22 Swedish Orphan Biovitrum
  11.22.1 Swedish Orphan Biovitrum Company Information
  11.22.2 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Offered
  11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.22.4 Swedish Orphan Biovitrum Main Business Overview
  11.22.5 Swedish Orphan Biovitrum Latest Developments
11.23 Biogen
  11.23.1 Biogen Company Information
  11.23.2 Biogen Non-oncology Biopharmaceuticals Product Offered
  11.23.3 Biogen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2020-2025)
  11.23.4 Biogen Main Business Overview
  11.23.5 Biogen Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Non-oncology Biopharmaceuticals Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Non-oncology Biopharmaceuticals Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Biologics
Table 4. Major Players of Biosimilars
Table 5. Non-oncology Biopharmaceuticals Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Non-oncology Biopharmaceuticals Market Size by Type (2020-2025) & ($ millions)
Table 7. Global Non-oncology Biopharmaceuticals Market Size Market Share by Type (2020-2025)
Table 8. Non-oncology Biopharmaceuticals Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Non-oncology Biopharmaceuticals Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Non-oncology Biopharmaceuticals Market Size Market Share by Application (2020-2025)
Table 11. Global Non-oncology Biopharmaceuticals Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Non-oncology Biopharmaceuticals Revenue Market Share by Player (2020-2025)
Table 13. Non-oncology Biopharmaceuticals Key Players Head office and Products Offered
Table 14. Non-oncology Biopharmaceuticals Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Non-oncology Biopharmaceuticals Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Non-oncology Biopharmaceuticals Market Size Market Share by Region (2020-2025)
Table 19. Global Non-oncology Biopharmaceuticals Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Non-oncology Biopharmaceuticals Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Non-oncology Biopharmaceuticals Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Non-oncology Biopharmaceuticals Market Size Market Share by Country (2020-2025)
Table 23. Americas Non-oncology Biopharmaceuticals Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas Non-oncology Biopharmaceuticals Market Size Market Share by Type (2020-2025)
Table 25. Americas Non-oncology Biopharmaceuticals Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Non-oncology Biopharmaceuticals Market Size Market Share by Application (2020-2025)
Table 27. APAC Non-oncology Biopharmaceuticals Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Non-oncology Biopharmaceuticals Market Size Market Share by Region (2020-2025)
Table 29. APAC Non-oncology Biopharmaceuticals Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC Non-oncology Biopharmaceuticals Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Non-oncology Biopharmaceuticals Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Non-oncology Biopharmaceuticals Market Size Market Share by Country (2020-2025)
Table 33. Europe Non-oncology Biopharmaceuticals Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe Non-oncology Biopharmaceuticals Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Non-oncology Biopharmaceuticals
Table 39. Key Market Challenges & Risks of Non-oncology Biopharmaceuticals
Table 40. Key Industry Trends of Non-oncology Biopharmaceuticals
Table 41. Global Non-oncology Biopharmaceuticals Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global Non-oncology Biopharmaceuticals Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global Non-oncology Biopharmaceuticals Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global Non-oncology Biopharmaceuticals Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Roche Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 46. Roche Non-oncology Biopharmaceuticals Product Offered
Table 47. Roche Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Roche Main Business
Table 49. Roche Latest Developments
Table 50. Sanofi Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 51. Sanofi Non-oncology Biopharmaceuticals Product Offered
Table 52. Sanofi Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Sanofi Main Business
Table 54. Sanofi Latest Developments
Table 55. Johnson & Johnson Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 56. Johnson & Johnson Non-oncology Biopharmaceuticals Product Offered
Table 57. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Johnson & Johnson Main Business
Table 59. Johnson & Johnson Latest Developments
Table 60. Pfizer Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 61. Pfizer Non-oncology Biopharmaceuticals Product Offered
Table 62. Pfizer Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Pfizer Main Business
Table 64. Pfizer Latest Developments
Table 65. Novo Nordisk Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 66. Novo Nordisk Non-oncology Biopharmaceuticals Product Offered
Table 67. Novo Nordisk Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Novo Nordisk Main Business
Table 69. Novo Nordisk Latest Developments
Table 70. Novartis Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 71. Novartis Non-oncology Biopharmaceuticals Product Offered
Table 72. Novartis Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Novartis Main Business
Table 74. Novartis Latest Developments
Table 75. Merck Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 76. Merck Non-oncology Biopharmaceuticals Product Offered
Table 77. Merck Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Merck Main Business
Table 79. Merck Latest Developments
Table 80. Teva Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 81. Teva Non-oncology Biopharmaceuticals Product Offered
Table 82. Teva Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Teva Main Business
Table 84. Teva Latest Developments
Table 85. Eli Lilly Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 86. Eli Lilly Non-oncology Biopharmaceuticals Product Offered
Table 87. Eli Lilly Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Eli Lilly Main Business
Table 89. Eli Lilly Latest Developments
Table 90. Bristol-Myers Squibb Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 91. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Offered
Table 92. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. Bristol-Myers Squibb Main Business
Table 94. Bristol-Myers Squibb Latest Developments
Table 95. GlaxoSmithKline Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 96. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Offered
Table 97. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 98. GlaxoSmithKline Main Business
Table 99. GlaxoSmithKline Latest Developments
Table 100. UCB Pharma Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 101. UCB Pharma Non-oncology Biopharmaceuticals Product Offered
Table 102. UCB Pharma Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 103. UCB Pharma Main Business
Table 104. UCB Pharma Latest Developments
Table 105. Amgen Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 106. Amgen Non-oncology Biopharmaceuticals Product Offered
Table 107. Amgen Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 108. Amgen Main Business
Table 109. Amgen Latest Developments
Table 110. AbbVie Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 111. AbbVie Non-oncology Biopharmaceuticals Product Offered
Table 112. AbbVie Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 113. AbbVie Main Business
Table 114. AbbVie Latest Developments
Table 115. Takeda Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 116. Takeda Non-oncology Biopharmaceuticals Product Offered
Table 117. Takeda Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 118. Takeda Main Business
Table 119. Takeda Latest Developments
Table 120. AstraZeneca Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 121. AstraZeneca Non-oncology Biopharmaceuticals Product Offered
Table 122. AstraZeneca Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 123. AstraZeneca Main Business
Table 124. AstraZeneca Latest Developments
Table 125. Mylan Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 126. Mylan Non-oncology Biopharmaceuticals Product Offered
Table 127. Mylan Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 128. Mylan Main Business
Table 129. Mylan Latest Developments
Table 130. LEO Pharma Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 131. LEO Pharma Non-oncology Biopharmaceuticals Product Offered
Table 132. LEO Pharma Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 133. LEO Pharma Main Business
Table 134. LEO Pharma Latest Developments
Table 135. Boehringer Ingelheim Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 136. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Offered
Table 137. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 138. Boehringer Ingelheim Main Business
Table 139. Boehringer Ingelheim Latest Developments
Table 140. Alexion Pharmaceuticals Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 141. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Offered
Table 142. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 143. Alexion Pharmaceuticals Main Business
Table 144. Alexion Pharmaceuticals Latest Developments
Table 145. Elusys Therapeutics Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 146. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Offered
Table 147. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 148. Elusys Therapeutics Main Business
Table 149. Elusys Therapeutics Latest Developments
Table 150. Swedish Orphan Biovitrum Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 151. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Offered
Table 152. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 153. Swedish Orphan Biovitrum Main Business
Table 154. Swedish Orphan Biovitrum Latest Developments
Table 155. Biogen Details, Company Type, Non-oncology Biopharmaceuticals Area Served and Its Competitors
Table 156. Biogen Non-oncology Biopharmaceuticals Product Offered
Table 157. Biogen Non-oncology Biopharmaceuticals Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 158. Biogen Main Business
Table 159. Biogen Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Non-oncology Biopharmaceuticals Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Non-oncology Biopharmaceuticals Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Non-oncology Biopharmaceuticals Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Non-oncology Biopharmaceuticals Sales Market Share by Country/Region (2024)
Figure 8. Non-oncology Biopharmaceuticals Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Non-oncology Biopharmaceuticals Market Size Market Share by Type in 2024
Figure 10. Non-oncology Biopharmaceuticals in Immunology
Figure 11. Global Non-oncology Biopharmaceuticals Market: Immunology (2020-2025) & ($ millions)
Figure 12. Non-oncology Biopharmaceuticals in Endocrinology
Figure 13. Global Non-oncology Biopharmaceuticals Market: Endocrinology (2020-2025) & ($ millions)
Figure 14. Non-oncology Biopharmaceuticals in Others
Figure 15. Global Non-oncology Biopharmaceuticals Market: Others (2020-2025) & ($ millions)
Figure 16. Global Non-oncology Biopharmaceuticals Market Size Market Share by Application in 2024
Figure 17. Global Non-oncology Biopharmaceuticals Revenue Market Share by Player in 2024
Figure 18. Global Non-oncology Biopharmaceuticals Market Size Market Share by Region (2020-2025)
Figure 19. Americas Non-oncology Biopharmaceuticals Market Size 2020-2025 ($ millions)
Figure 20. APAC Non-oncology Biopharmaceuticals Market Size 2020-2025 ($ millions)
Figure 21. Europe Non-oncology Biopharmaceuticals Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Non-oncology Biopharmaceuticals Market Size 2020-2025 ($ millions)
Figure 23. Americas Non-oncology Biopharmaceuticals Value Market Share by Country in 2024
Figure 24. United States Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Non-oncology Biopharmaceuticals Market Size Market Share by Region in 2024
Figure 29. APAC Non-oncology Biopharmaceuticals Market Size Market Share by Type (2020-2025)
Figure 30. APAC Non-oncology Biopharmaceuticals Market Size Market Share by Application (2020-2025)
Figure 31. China Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 35. India Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Non-oncology Biopharmaceuticals Market Size Market Share by Country in 2024
Figure 38. Europe Non-oncology Biopharmaceuticals Market Size Market Share by Type (2020-2025)
Figure 39. Europe Non-oncology Biopharmaceuticals Market Size Market Share by Application (2020-2025)
Figure 40. Germany Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 41. France Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Non-oncology Biopharmaceuticals Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 54. APAC Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 55. Europe Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 57. United States Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 58. Canada Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 59. Mexico Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 60. Brazil Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 61. China Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 62. Japan Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 63. Korea Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 65. India Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 66. Australia Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 67. Germany Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 68. France Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 69. UK Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 70. Italy Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 71. Russia Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 72. Egypt Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 73. South Africa Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 74. Israel Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 75. Turkey Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)
Figure 76. Global Non-oncology Biopharmaceuticals Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Non-oncology Biopharmaceuticals Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Non-oncology Biopharmaceuticals Market Size 2026-2031 ($ millions)